NUREMBERG, Germany, May 16, 2011 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that Vical is presenting on the company's TransVax™ therapeutic cytomegalovirus (CMV) vaccine, and its CMV research collaborators are presenting on new vaccine approaches for prevention of congenital CMV infection, both at the 13th International CMV/BetaHerpesvirus Workshop (Nuremberg, Germany – May 14-17).
